Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/31942
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorNERI, Lenycia de Cassya Lopes
dc.contributor.authorTAMINATO, Monica
dc.contributor.authorSILVA FILHO, Luiz Vicente Ribeiro Ferreira da
dc.date.accessioned2019-05-30T13:45:51Z
dc.date.available2019-05-30T13:45:51Z
dc.date.issued2019
dc.identifier.citationJOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, v.68, n.3, p.394-399, 2019
dc.identifier.issn0277-2116
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/31942
dc.description.abstractBackground: Cystic fibrosis (CF) is associated with chronic respiratory disease and pancreatic insufficiency and results in the malabsorption of nutrients and intestinal inflammation. There is evidence that probiotic supplementation may impact the gastrointestinal and respiratory microbiota. This study aimed to categorize current evidence regarding the effects of supplementing with probiotics in CF patients on gastrointestinal and respiratory outcomes according to the type of intervention. Methods: The initial database search included all identified studies according to the recommendations of the Cochrane Collaboration, regardless of language, publication date or design. Studies were categorized by probiotic strain (Lactobacillus reuteri; Lactobacillus rhamnosus GG or a mix of strains); dosage (low dosage if <10(9) CFU [ colony forming units] or high dosage if >10(9) CFU); and duration of intervention (1, 3, 6, or 12 months). Assessment of quality was performed based on the Cochrane risk of bias criteria and the Downs & Black checklist. Results: A total of 205 studies were identified; however, only 9 met the criteria for inclusion. The studies were considered to have a high risk of bias, hampering the possibility of performing a meta-analysis. Eighty percent of the studies (4 of 5) reported a positive result for intestinal inflammation, and another 4 studies (4 of 5) reported a positive result for pulmonary exacerbation frequency, regardless of the treatment approach. Conclusions: The present data indicate a promising future for probiotic use in cystic fibrosis, which has an impact on exacerbations and intestinal inflammation; however, further studies of standardized therapeutic interventions are required.eng
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINSeng
dc.relation.ispartofJournal of Pediatric Gastroenterology and Nutrition
dc.rightsrestrictedAccesseng
dc.subjectcystic fibrosiseng
dc.subjectintestinal inflammationeng
dc.subjectprobioticseng
dc.subjectpulmonary exacerbationeng
dc.subject.otherquality-of-lifeeng
dc.subject.otherpulmonary exacerbationseng
dc.subject.otherintestinal inflammationeng
dc.subject.othersupplementationeng
dc.subject.othermicrobiotaeng
dc.subject.otheroutcomeseng
dc.subject.otherchildreneng
dc.titleSystematic Review of Probiotics for Cystic Fibrosis Patients: Moving Forwardeng
dc.typearticleeng
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINSeng
dc.identifier.doi10.1097/MPG.0000000000002185
dc.identifier.pmid30358738
dc.subject.wosGastroenterology & Hepatologyeng
dc.subject.wosNutrition & Dieteticseng
dc.subject.wosPediatricseng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalTAMINATO, Monica:Univ Fed Sao Paulo, Sao Paulo, Brazil
hcfmusp.description.beginpage394
hcfmusp.description.endpage399
hcfmusp.description.issue3
hcfmusp.description.volume68
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000461077600028
hcfmusp.origem.id2-s2.0-85062067508
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAlexandre Y, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-107eng
hcfmusp.relation.referenceAnanthan A, 2016, EUR J PEDIATR, V175, P1255, DOI 10.1007/s00431-016-2769-8eng
hcfmusp.relation.referenceAnderson JL, 2017, J CYST FIBROS, V16, P186, DOI 10.1016/j.jcf.2016.09.004eng
hcfmusp.relation.referenceBlanco PG, 2004, AM J PHYSIOL-GASTR L, V287, pG491, DOI 10.1152/ajpgi.00452.2003eng
hcfmusp.relation.referenceBritto MT, 2002, CHEST, V121, P64, DOI 10.1378/chest.121.1.64eng
hcfmusp.relation.referenceBruzzese E, 2004, ALIMENT PHARM THER, V20, P813, DOI 10.1111/j.1365-2036.2004.02174.xeng
hcfmusp.relation.referenceBruzzese E, 2007, CLIN NUTR, V26, P322, DOI 10.1016/j.clnu.2007.01.004eng
hcfmusp.relation.referenceBruzzese E, 2018, J CYST FIBROS, V17, P375, DOI 10.1016/j.jcf.2017.10.014eng
hcfmusp.relation.referenceBruzzese E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087796eng
hcfmusp.relation.referenceCotar Ani Ioana, 2010, Roum Arch Microbiol Immunol, V69, P213eng
hcfmusp.relation.referencede Freitas MB, 2018, EUR J CLIN NUTR, V72, P736, DOI 10.1038/s41430-017-0043-4eng
hcfmusp.relation.referencedel Campo R, 2014, J CYST FIBROS, V13, P716, DOI 10.1016/j.jcf.2014.02.007eng
hcfmusp.relation.referenceDi Nardo G, 2014, J PEDIATR GASTR NUTR, V58, P81, DOI 10.1097/MPG.0000000000000187eng
hcfmusp.relation.referenceDorsey Jill, 2017, J Cyst Fibros, V16 Suppl 2, pS14, DOI 10.1016/j.jcf.2017.07.014eng
hcfmusp.relation.referenceDowns SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377eng
hcfmusp.relation.referenceFallahi G, 2013, TURKISH J PEDIATR, V55, P475eng
hcfmusp.relation.referenceFAO/WHO, 2002, GUID EV PROB FOODeng
hcfmusp.relation.referenceGIBSON GR, 1995, J NUTR, V125, P1401, DOI 10.1093/jn/125.6.1401eng
hcfmusp.relation.referenceHiggins J, 2005, COCHRANE HDB SYSTEMAeng
hcfmusp.relation.referenceHiggins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928eng
hcfmusp.relation.referenceHoen AG, 2015, J PEDIATR-US, V167, P138, DOI 10.1016/j.jpeds.2015.02.049eng
hcfmusp.relation.referenceInfante Pina D, 2008, An Pediatr (Barc), V69, P501eng
hcfmusp.relation.referenceJafari SA, 2013, IRAN J PEDIATR, V23, P669eng
hcfmusp.relation.referenceLin L, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-016-0187-3eng
hcfmusp.relation.referenceLiou TG, 2001, AM J EPIDEMIOL, V153, P345, DOI 10.1093/aje/153.4.345eng
hcfmusp.relation.referenceMorais Mauro Batista de, 2006, J. Pediatr. (Rio J.), V82, pS189, DOI 10.1590/S0021-75572006000700009eng
hcfmusp.relation.referenceNikniaz Z, 2017, WORLD J PEDIATR, V13, P307, DOI 10.1007/s12519-017-0033-6eng
hcfmusp.relation.referencePutignani L, 2014, PEDIATR RES, V76, P2, DOI 10.1038/pr.2014.49eng
hcfmusp.relation.referenceRalhan A, 2016, J INNATE IMMUN, V8, P531, DOI 10.1159/000446840eng
hcfmusp.relation.referenceRogers GB, 2016, PEDIATR PULM, V51, pS35, DOI 10.1002/ppul.23544eng
hcfmusp.relation.referenceRubin JL, 2017, CURR MED RES OPIN, V33, P667, DOI 10.1080/03007995.2016.1277196eng
hcfmusp.relation.referenceVan Biervliet S, 2017, CLIN NUTR ESPEN, V18, P37, DOI 10.1016/j.clnesp.2017.01.007eng
hcfmusp.relation.referenceWeiss B, 2010, PEDIATR PULM, V45, P536, DOI 10.1002/ppul.21138eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1536-4801
hcfmusp.citation.scopus12-
hcfmusp.scopus.lastupdate2022-06-10-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICr
Instituto da Criança - HC/ICr

Artigos e Materiais de Revistas Científicas - LIM/36
LIM/36 - Laboratório de Pediatria Clínica

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_NERI_Systematic_Review_of_Probiotics_for_Cystic_Fibrosis_Patients_2019.PDF
  Restricted Access
publishedVersion (English)464.85 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.